About Kailera Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.kailera.com
Frequently Asked Questions
What is the 52-week range for KLRA?
The 52-week high is $28.2271 and the 52-week low is $10.565.
What is the P/E ratio for KLRA?
The P/E ratio data is currently unavailable.
What is the dividend yield for KLRA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for KLRA over the last few months:
Latest KLRA News
GLP-1s: Still Early In The Growth Story
The GLP-1 market continues to expand rapidly yet remains in the early stages of growth. The GLP-1 market is no longer simply a weight-loss story.
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing th
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Could this be what Novo needs to turn things around?
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
Kailera Therapeutics (KLRA) said Wednesday that enrollment in the KaiNETIC global phase 3 clinical p
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program,
Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher- Topline data now expected in mid-2028WALTHAM, Mass., Sept. 30, 2026
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation
Kailera Therapeutics initiated with a Hold rating due to efficacy data released and long timelines for key catalysts. Click for key KLRA catalysts and risks.
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Kailera Therapeutics, Inc. has three promising GLP-1 drug candidates and may secure commercial approval for ribupatide by 2029. Click for more on KLRA's rating.
Kailera Therapeutics to Participate in September Investor Conferences
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare ForumWednesday, September 23, 2026, 9:40 a.m. ETFireside Chat with Jamie Coleman, Chief Commercial Officer Stifel 2026 Virtual Cardiometabolic ForumWednesday,
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here’s the problem. Let’s say I say buy it. It’s just the most speculative stock on Earth. […]
Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’
Jim Cramer favors Texas Pacific Land, calls Kailera his speculative pick, and criticizes P&G, Ondas and Tractor Supply.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-07 | Nicholson Nur | +220,000 | - | - |
| 2026-07-06 | Tregoning Kathleen | +175,000 | - | - |
| 2026-06-09 | Renaud Ronald C JR | -38,094 | - | - |
| 2026-06-09 | Renaud Ronald C JR | +38,094 | $5.25 | $199,994 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | -708,814 | - | - |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | -4,968,789 | - | - |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | +2,034,133 | - | - |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | +9,477,719 | - | - |
| 2026-04-20 | RTW INVESTMENTS, LP | -2,026,820 | - | - |
| 2026-04-20 | RTW INVESTMENTS, LP | -8,250,000 | - | - |
| 2026-04-20 | RTW INVESTMENTS, LP | +500,000 | $16 | $8,000,000 |
| 2026-04-20 | RTW INVESTMENTS, LP | +10,276,820 | - | - |